arrow
A

Aparna Chhibber

translational medicine oncology
H指数:21
被引数:4,626

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial

出版物简明摘要:比较在CheckMate 7FL临床试验中,对于新诊断的雌激素受体阳性乳腺癌患者,使用纳武利尤单抗联合新辅助化疗与安慰剂联合新辅助化疗的疗效。

2025-10-010
PRE
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial

纳武利尤单抗联合化疗或伊匹木单抗治疗胃癌和食管癌:一项随机III期试验的探索性生物标志物分析

2025-03-070
OA
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab
2024-07-190
OA
CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods

CAGI,基因组解释的关键评估,建立了计算遗传变异解释方法的进展和前景

2024-02-2210
OAAI
MECHANISM OF ACTION OF BEMPEGALDESLEUKIN (BEMPEG) PLUS NIVOLUMAB (NIVO) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA FROM THE PHASE 3 RANDOMIZED OPEN-LABEL PIVOT IO-001 CLINICAL TRIAL
2022-11-072
OA
A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment
2020-10-2636
PREAI
Lessons from the CAGI-4 Hopkins clinical panel challenge
2017-06-127
OAAI